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Abstract
Introduction: Systemic lupus erythematosus is a chronic autoimmune disease characterized by an abundance of
autoantibodies against nuclear antigens. Bruton’s tyrosine kinase (Btk) is a proximal transducer of the BCR signal
that allows for B-cell activation and differentiation. Recently, selective inhibition of Btk by PCI-32765 has shown
promise in limiting activity of multiple cells types in various models of cancer and autoimmunity. The aim of this
study was to determine the effect of Btk inhibition by PCI-32765 on the development of lupus in lupus-prone B6.
Sle1 and B6.Sle1.Sle3 mice.
Methods: B6.Sle1 or B6.Sle1.Sle3 mice received drinking water containing either the Btk inhibitor PCI-32765 or
vehicle for 56 days. Following treatment, mice were examined for clinical and pathological characteristics of lupus.
The effect of PCI-32765 on specific cell types was also investigated.
Results: In this study, we report that Btk inhibition dampens humoral autoimmunity in B6.Sle1 monocongenic
mice. Moreover, in B6.Sle1.Sle3 bicongenic mice that are prone to severe lupus, Btk inhibition also dampens
humoral and cellular autoimmunity, as well as lupus nephritis.
Conclusions: These findings suggest that partial crippling of cell signaling in B cells and antigen presenting cells
(APCs) may be a viable alternative to total depletion of these cells as a therapeutic modality for lupus.
Introduction
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease characterized by the presence of autoan-
tibodies, particularly against nuclear self-antigens. The
recognition of these antigens by their cognate antibodies
and the resultant deposition of immune complexes leads
to the development of a chronic inflammatory state,
which can have devastating effects on multiple end organ
targets including the kidneys, the cardiovascular system,
the skin, and the central nervous system. While the exact
etiology of SLE is unclear, it is well established that SLE
is a polygenic disorder with multiple dysregulated hema-
topoietic cell types contributing to the full-fledged dis-
ease state. To this end, it has been challenging to devise
effective therapies for SLE given that multiple cellular
and molecular checkpoints go awry in lupus. Bruton’s
tyrosine kinase (Btk) is intriguing as a potential therapeu-
tic target in SLE given its proximal location in the B cell
receptor (BCR) signaling cascade, as well as its previously
described role in multiple myeloid cell types [1-5].
Many studies have focused on the role of B cells in
lupus, and B cells have historically been a main target for
SLE therapeutic interventions. Despite numerous studies
and approaches to this problem, the goal of limiting the B
cell response in SLE remains elusive [6]. Near-total elimi-
nation of B cells is problematic because it is becoming
increasingly evident that B cells serve a number of other
functions besides antibody (and autoantibody) production.
These critical processes include T cell survival and anergy,
promotion of regulatory T cells, and synthesis of anti-
inflammatory cytokines, amongst others. Therefore, a
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more nuanced approach focused on dampening the B cell
response may prove to be more beneficial in SLE.
Since B cell activation is achieved through BCR signal-
ing, members of the BCR signaling cascade are of particu-
lar interest for study with regards to SLE. Btk has been a
prime target due to its proximal location in the pathway
and its direct link to B cell survival through NF-B [7,8].
In humans, Btk plays a critical role in the development of
B cells and subsequent antibody production, and mutation
of the Btk gene results in X-linked agammaglobulinemia,
which is characterized by low peripheral B cell numbers as
well as low serum immunoglobulin titers [9]. Similarly,
mutation or deletion of the Btk gene in mice leads to
X-linked immunodeficiency (xid), characterized by a sig-
nificant decrease in B1 and B2 B cells as well as signifi-
cantly decreased serum immunoglobulin levels [9].
Although Btk is expressed in other hematopoietic lineages
(but not T cells), the clinical phenotype of these genetic
conditions is dominated by B cell immunodeficiency. It
has long been appreciated that Btk is necessary for the
production of autoantibodies in multiple murine models
of lupus [10-12], and more recently it has been shown that
constitutive activation of Btk in B cells results in the accu-
mulation of autoreactive plasma cells [13]. Cell type-speci-
fic overexpression of Btk in B cells has recently been
shown to lead to spontaneous germinal center and plasma
cell formation, followed by autoantibody production [14].
However, even partial restoration of Btk by a low dose
transgene in lyn/btk-double deficient mice results in abro-
gation of anti-nuclear antibodies [15]. Given the connec-
tion between B cell over-activity and various disease states,
Btk has been investigated as a pathogenic target in multi-
ple disease models. To this end, xid mice have been
reported to be resistant to collagen-induced arthritis [16],
and inhibition of Btk has been shown to be effective in
treating various cancers as well as autoimmune diseases
[17-20].
The NZM2410 mouse strain develops spontaneous
lupus nephritis that shares a number of characteristics
with human SLE [21]. Linkage analysis has uncovered sev-
eral chromosomal intervals responsible for conferring
lupus susceptibility in this strain [22]. By introgressing
these intervals onto the healthy lupus-resistant C57BL/6
(B6) mouse strain, researchers have been able to deter-
mine the role of each locus in disease development. The
presence of the Sle1 locus on the B6 background has been
shown to be responsible for breaching immune tolerance
to nuclear antigens. These mice display increased autoan-
tibodies specific for chromatin, autoreactive T cells
responding to histone epitopes, and enhanced expression
of activation markers on T and B cells leading to func-
tional defects in both cell types [23,24]. Meanwhile, the
Sle3 locus introgressed onto the B6 background demon-
strates dysregulated T cells as evidenced by hyperactivity
and skewed CD4:CD8 ratios as a result of hyper-stimula-
tory antigen presenting cells (APCs) [25,26]. The Sle3
locus also confers some resistance to bacterial infections,
further suggesting a role for this locus in the proper func-
tioning of APCs [27]. Taken together, these data suggest a
predominantly B cell-mediated role for the Sle1 locus and
a predominantly innate immunity-targeted role for the
Sle3 locus in lupus development. While the introduction
of any single NZM2410-derived locus has not been shown
to recapitulate complete disease, the presence of both the
Sle1 locus and the Sle3 locus on the B6 background results
in severe glomerulonephritis, reinforcing the notion that
multiple genetic alterations in several cell types may be
necessary to drive lupus pathogenesis [28].
Here, we have utilized mouse models bearing these
lupus susceptibility loci to investigate the therapeutic
potential of Btk in a spontaneous murine model of lupus
nephritis by treating the mice with a small molecule Btk-
inhibitor, PCI-32765; this is an irreversible inhibitor that
binds covalently to Cys-481 of Btk with an IC50 of about
0.5 nM in biochemical assays. PCI-32765 is currently in
phase II trials for treatment of B cell malignancies, and
preliminary results demonstrate that approximately 60 to
70% of patients with relapsed and refractory chronic lym-
phocytic leukemia (CLL) or mantle cell lymphoma (MCL)
respond to the drug [29,30].
Materials and methods
Mice
For these studies all mice were bred and housed at the
University of Texas Southwestern Medical Center in Dal-
las, TX, USA. The studies were designed in conjunction
with Pharmacylics, Inc. (Sunnyvale, CA, USA), and were
conducted with the prior approval of the University of
Texas Southwestern Medical Center Institutional Animal
Care and Use Committee. Based on the typical age of phe-
notype development in these models 8-month-old male
and female B6.Sle1 and pre-disease 4-month-old female
B6.Sle1.Sle3 mice were used for the experiments. Autoan-
tibody levels were examined prior to the start of treatment
to ensure the mice were at similar stages of disease. Both
sets of mice were treated for two months and then sacri-
ficed to ensure that mice did not succumb to disease
before the data could be collected.
Drug formulation
PCI-32765 (Pharmacyclics Inc.) was formulated in sterile-
filtered 1% HP-beta-cyclodextrin in distilled water. The
drug was provided in drinking water at 0.16 mg/mL,
which is an estimated dose of 30 mg/kg calculated based
on average water consumption. The vehicle was sterile-
filtered 1% HP-beta-cyclodextrin in distilled water. The
amount of drug- or vehicle-containing water consumed
was approximately 3.5 to 4.0 mL per mouse per day and
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was similar between groups and cages (data not shown).
Splenocytes were isolated from B6.Sle1.Sle3 mice treated
with PCI-32765 after sacrifice on day 56 and the phar-
maco-dynamic probe assay for Btk was performed as pre-
viously described [17].
Histopathology
Kidneys isolated from 6-month-old B6.Sle1.Sle3 mice were
cut laterally and fixed in phosphate-buffered 10% formalin,
processed in paraffin blocks and cut into 5-μm sections.
Sections were stained with periodic-acid Schiff (PAS) or
H&E and examined by light microscopy for evidence of
inflammation or tissue damage. At least 100 glomeruli per
section were examined and scoring (0 to 4) of renal
damage was done by a pathologist blinded to the study, as
detailed previously [31].
Autoantibody ELISA
Ninety-six-well plates were pre-coated with methylated
BSA before the addition of double stranded DNA, single
stranded DNA, histones, or double stranded DNA and
then histones (nucleosomes) as detailed previously [31].
After incubation, the plates were washed, sera from the
study mice were added to the wells, and the plates were
again incubated. After washing off the unbound sera, alka-
line phosphatase-conjugated goat anti-mouse IgG or IgM
antibodies were added. Autoantibody titers were deter-
mined by the absorbance read at 405 nm on an ELx808
plate reader (BioTek, Winooski, VT, USA).
Flow cytometry
Spleens and kidneys were isolated from mice following
sacrifice and perfusion. For the spleens, a single cell suspen-
sion was obtained by crushing the spleen through a 100-
micron mesh filter and washing the cells. Red blood cells
were lysed using PharmLyse (BD Biosciences, San Diego,
CA, USA). Kidneys were minced with a razor blade and
treated with collagenase for 30 minutes at 37°C with shak-
ing. Following collagenase treatment, cells were immedi-
ately placed on ice and the collagenase activity was stopped
by dilution with media containing fetal bovine serum. Red
blood cells were lysed in a similar manner to splenocytes
and cell clumps were disrupted by syringe and then forced
through a 100-micron filter. Cells were stained with antibo-
dies against AA4.1, B220, CD4, CD5, CD8, CD11b, CD11c,
CD21/35, CD23, CD34, CD45, CD62L, CD69, CD138, c-
Kit, GL-7, Ly6C, Ly6G (BD Biosciences) and F4/80 (Invitro-
gen, San Diego, CA). All samples were run on an LSRII
flow cytometer (BD Biosciences) in the University of Texas
Southwestern Medical Center Flow Cytometry Core.
Statistics
All statistical analyses were done by two-tailed Student’s
t-test with Welch’s correction.
Results
PCI-32765 checks the increase in autoantibodies inherent
to the Sle1 locus
While C57BL/6 mice do not spontaneously develop
lupus, the presence of the Sle1 locus from the NZM2410
lupus-prone strain results in the development of autoan-
tibodies, especially anti-histone and anti-nucleosome
antibodies, as well as hyperactivated T and B cells
[23,24]. Given that the Sle1 locus has previously been
shown to be related to a defect in B cell tolerance, we tar-
geted the proximal BCR-mediated signaling molecule Btk
by treating B6.Sle1 mice with PCI-32765, to examine the
impact of disrupting BCR-signaling on autoantibody
development. Although IgM isotype anti-ssDNA, anti-
nucleosome, and anti-histone antibodies did not show
significant differences following treatment, PCI-32765-
treated mice demonstrated reduced levels of IgG isotype
anti-histone, anti-nucleosome and anti-dsDNA levels,
with the latter attaining statistical significance (69%
reduction, P < 0.05), compared to day 0 levels in the
same mice (Figure 1). In contrast, circulating levels of all
measured autoantibodies increased in vehicle-treated
mice over the same time period (Figure 1). Taken
together these data indicate that Btk plays an important
role in both autoantibody production and isotype switch-
ing, with a more profound impact on class-switched IgG
autoantibodies. These data are similar to previous genetic
studies demonstrating that reduced Btk gene dosage pre-
ferentially affects IgG antibodies in 56R anti-DNA trans-
genic mice but both IgM and IgG antibodies in lyn-/- mice
[15,32]. Interestingly, the anti-histone and anti-nucleosome
titers that are most affected by PCI-32765 treatment
resemble the anti-nucleosome seroprofile previously attrib-
uted to Sle1 [23,24].
Inhibition of Btk results in a less severe Sle1 phenotype
Although the Sle1-bearing mice do not develop full
blown lupus-like disease, the Sle1 locus has been shown
to elicit lymphocyte activation and splenomegaly [23].
B6.Sle1 mice treated with PCI-32765 have no significant
change in total body weight compared to vehicle-treated
mice (Figure 2A); however the PCI-32765-treated mice
display a 43.3% decrease in spleen size and total spleno-
cytes compared to the vehicle-treated mice (4.90 × 107vs.
8.65 × 107 splenocytes, Figure 2B-C). This reduction in cell
number coincides with a decrease in activated CD4+ (28%)
and CD8+ (46%) T-cells, activated B-cells (53%), germinal
center B-cells (62%, P = 0.05, B220+GL7+), and plasma-
blasts (56%) relative to the vehicle group (Figure 2D). How-
ever, the number of myeloid cells, including dendritic cells
(CD11b+CD11c+), macrophages (CD11b+F4/80+), and
neutrophils (CD11b+Ly6G+) is not significantly changed
(data not shown). Taken together, these data suggest that
Btk plays an important role in regulating immune cell
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Figure 1 PCI-32765 dampens the production of anti-nuclear autoantibodies in B6.Sle1 mice. The indicated autoantibody ELISAs were
performed on sera isolated at the indicated day of treatment from mice either treated with PCI-32765 (black bars, n = 5) or a vehicle (grey bars,
n = 4). All values are the optical density (OD) readings at 405 nm wavelength. *P < 0.05, **P < 0.01 compared to day-0 values measured in the
same mice. D0, day zero; D56, day 56.
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activation in the context of lupus, affecting multiple cell
lineages.
PCI-32765 delays production of circulating autoantibodies
in Sle1.Sle3 bicongenic mice
Though Sle1 by itself is not sufficient for full-blown
lupus to ensue, bicongenics bearing both Sle1 and Sle3
develop lupus nephritis, likely as a result of a cumulative
impact on multiple cell types including both B cells and
APCs [33]. Given that the B6.Sle1.Sle3 mouse strain
develops more severe disease with spontaneous glomer-
ulonephritis around 6 months of age, we next treated 4-
month-old (pre-disease) B6.Sle1.Sle3 mice for 2 months
with either PCI-32765 (n = 9) or a vehicle (n = 8) to
determine if disease progression could be delayed or
halted. Following treatment, splenocytes from the mice
were isolated and assayed to ensure that PCI-32765 was
binding Btk as previously reported (Figure 3A) [17].
Mice that had been treated with the vehicle displayed a
thick band representative of unbound Btk. However, B6.
Sle1.Sle3 mice that received drinking water containing
PCI-32765 had significantly lighter bands, suggesting that
Btk had been bound by PCI-32765 in these mice. We
determined by densitometry that an average of 78.4% of
the Btk was bound by PCI-32765 in the treatment group
compared to the vehicle-treated mice (Figure 3A). The
total expression of Btk was not affected in the PCI-
32765-treated mice (Figure 3B).
Figure 2 Treatment with PCI-32765 affects spleen size and lymphocyte activation in B6.Sle1 mice. (A) Mice that received PCI-32765 are of
similar weight compared to vehicle treated mice. All mice were weighed before sacrifice. (B-C) PCI-32765 reduces splenomegaly, but not kidney
size, as measured by weight or cell number. Spleens and kidneys isolated from mice treated with PCI-32765 (n = 9) or vehicle (n = 8) for 56
days were weighed prior to the preparation of a single cell suspension of each tissue. Cells were then counted on a Cellometer Auto M10
automated cell counter (Nexcelom Bioscience, Lawrence, MA, USA). (D) Inhibition of Btk results in decreased lymphoid activation. Single cell
suspensions were prepared from isolated spleens and stained for flow cytometry analysis of the indicated lymphocyte populations and activation
status (CD69+). Each data point represents one mouse. Line represents mean ± standard error of the mean. *P < 0.05, **P < 0.005. Data were
compared by two-tailed Student’s t-test with Welch’s correction.
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As noted in the B6.Sle1 treatment studies, Btk blockade
also dampened autoantibody production in the bicongenic
lupus strain. By day 28, the mice receiving the Btk-inhibitor
displayed significantly reduced levels of both IgM and IgG
anti-nucleosome and anti-histone antibodies (Figure 4).
This reduction of circulating anti-nucleosome and anti-his-
tone antibodies was sustained through day 56, by which
time point anti-ssDNA (but not anti-dsDNA) antibodies
were also reduced (Figure 4).
PCI-32765 reduces splenomegaly and leukocyte activation
in lupus-prone Sle1.Sle3 mice
After two months of treatment, spleen weights of the
sacrificed animals were reduced by 58% in the treated
mice (84.4 mg vs. 199 mg, P = 0.005, Figure 5B). Splenic
cell count was reduced by 70% (1.94 × 108vs. 5.9 × 107,
P = 0.008) in these mice compared to the vehicle-treated
mice (Figure 5C). In contrast, the size and cellularity of
the kidneys were not significantly reduced by PCI-32765
treatment, nor was the overall body weight (Figure 5A-C).
Flow cytometric analysis revealed significant decreases in
splenic populations of multiple cell types in mice treated
with PCI-32765 (Table 1), including total splenic B cells
(71.5%, P < 0.05), activated B cells (74.9%, P < 0.01), and B
cells from multiple stages of development including T1
(64%, P < 0.05) and T2 transitional B cells (78.6%, P <
0.01), mature marginal zone (74.6%, P < 0.05) and follicu-
lar B cells (63.2%, P < 0.05), and plasmablasts (74.5%, P <
0.01). Given that Btk has also been described in multiple
myeloid cell types, these cell populations were also
examined in mice treated with PCI-32765 (n = 9) com-
pared to vehicle-treated mice (n = 8). Significant decreases
were observed in myeloid dendritic cells (79.2%, P <
0.005), macrophages (76.4%, P < 0.01), neutrophils (68.1%,
P < 0.01), mast cells (80.3%, P < 0.02), and CD11b+Ly6C
+CD62L- (73.6%, P < 0.05) cells, which may represent
newly infiltrating inflammatory monocytes, as summarized
in Table 1. Interestingly, despite the lack of a T cell speci-
fic role for Btk, multiple splenic T cell populations from
both T helper and cytotoxic T cell lineages were also
impacted by treatment with PCI-32765. These significantly
reduced T cell populations included total T helper cells
(82.7%, P < 0.01), activated T helpers (83.6%, P < 0.005),
and both central (84.6%, P < 0.05) and effector (80.5%, P <
0.01) memory T helper cells as well as total (80.8%, P <
0.01), central memory (75.5, P < 0.01) and effector mem-
ory (80.1%, P < 0.01) cytotoxic T cells (Table 1). Strikingly,
despite the significant decrease in splenic size following
PCI-32765 treatment, there was no difference in the num-
ber of naïve CD4+ T helper or naïve CD8+ cytotoxic
T cell populations. Taken together, these data suggest that
treatment with PCI-32765 skews T cells towards a less
activated phenotype, likely as a result of decreased B cell
and APC activation.
Reduced renal damage and lymphocyte infiltration in
PCI-32765-treated mice
To determine if treatment with PCI-32765 was able to
limit renal damage, paraffin-embedded kidneys from B6.
Sle1.Sle3 mice treated with either PCI-32765 (n = 9) or
Figure 3 Inhibition of Bruton’s tyrosine kinase (Btk) by PCI-32765. (A) Fluorescent gel scan of splenic lysates from mice that had been
treated with PCI-32765 or vehicle. Cells were incubated with the affinity probe PCI-33380, a fluorescently tagged derivative of PCI-32765, prior to
lysis and visualization by SDS-PAGE. Binding of PCI-33380 indicates unbound Btk was available in the cells. The arrow indicates the predominant
band labeled by the probe (at approximately 76 kDa, the expected molecular weight of Btk). The percentage of occupancy is based on
densitometry relative to the vehicle-treated samples. (B) Total Btk expression was determined by western blot.
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Figure 4 Inhibition of Btk limits increase of IgM isotype autoantibodies and results in decrease of IgG isotype autoantibodies in B6.
Sle1.Sle3 mice. The indicated autoantibody ELISAs were performed on sera routinely isolated from mice either treated with PCI-32765 or
vehicle. All values are the optical density (OD) readings at 405 nm wavelength. Thick grey dashed line indicates vehicle, black line indicates
PCI-32765. Thin dashed line indicates serum antibodies in 2-month-old lupus-resistant B6 sample indicative of negative control. All data points
represent the mean ± standard error of the mean. *P < 0.05. Samples were compared by two-tailed Student’s t-test with Welch’s correction. D0,
day zero, D28, day 28; D56, day 56.
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vehicle (n = 6) were sectioned, stained and scored by a
pathologist who remained blind to sample identities.
While the kidneys from the vehicle-treated mice had
moderate damage (glomerular nephritis (GN) score
2.67 ± 0.25, n = 6), the PCI-32765-treated mice dis-
played significantly less renal damage (GN score 1.39 ±
0.16, n = 9, P < 0.02, Figure 5A, C). There was also a
corresponding decrease in the number of infiltrating
lymphocytes in the kidneys. Despite similar numbers of
total intra-renal cells in both groups (Figure 6A), there
were significantly fewer B220+ B-cells (59% decrease,
P < 0.01) in the kidneys of B6.Sle1.Sle3 mice that
received PCI-32765 compared to mice that received the
vehicle (Figure 6B).
Discussion
When cells are initially confronted with antigens, each cell
is at a crossroads from which the cell can either become
activated and begin an immune response, or be eliminated
through anergy induction or apoptosis. Autoimmunity at
its most basic level, is characterized by the improper
response to self-antigens leading to activation of an
immune response. Historically, treatment for SLE has
been limited to general immune suppressive drugs, includ-
ing corticosteroids, anti-malarial drugs, and cyclophospha-
mide, all of which are limited in their efficacy and are
associated with deleterious side effects [34]. The recent US
Food and Drug Administration (FDA) approval of belimu-
mab, an inhibitor of B lymphocyte stimulator (BLyS), for
the treatment of SLE patients has highlighted a new wave
of signaling targets that are being therapeutically exploited
with some encouraging results in lupus. These novel can-
didates include a variety of intracellular proteins such as
calmodulin kinase, calcineurin, heat shock protein 90 and
Rho, as reviewed [34,35]. In B cells, one potential mechan-
ism for accomplishing this is to disrupt BCR signaling, as
the BCR is responsible for delivering maturation signals to
immature and mature B cells. Inhibition of the BCR-com-
ponent, spleen tyrosine kinase (Syk), has shown promise
in attenuating skin and renal manifestations of lupus in
certain mouse models [36], although translation to human
trials may be complicated by the expression of Syk on a
number of cell types. Another such target within the BCR-
signaling cascade is Btk.
Btk is a particularly attractive target in this signaling cas-
cade because it has a specific role in B cell activation and
survival. While xid- and Btk-deficient mice display a
marked reduction in mature B cells in the periphery, these
mice have normal numbers of pre-B and immature B cells
[37,38]. Furthermore, the loss of Btk function dampens
the ability of B cells to respond to signals from cell surface
receptors including the BCR, IL-10R, RP105, CD38, and
toll-like receptors (TLRs), amongst others [39-43]. Thus,
the addition of a Btk transgene to Btk-deficient mice
restores the mature B cell population but still does not
restore full response to BCR signals [44]. B cell response
to T-independent antigens are also reliant on Btk in a
dose-dependent fashion, as partial restoration of Btk
restores normal B cell response to type-II viral antigens
but not 2,4,6-trinitrophenol (TNP)-Ficoll. Taken together,
these data suggest that modulation of Btk levels can differ-
entially affect B-cell differentiation, survival, and function
without eliminating the majority of mature B-cells. There-
fore, our goal was to modulate, rather than completely
block, BCR signaling. Such inhibition of BTK with PCI-
32765 has recently been shown to be efficacious in
patients with B cell malignancies [19,45] as well as in mice
with autoimmune diseases [17,20].
Previously the Sle1 locus has been identified as being
crucial in breaking peripheral B cell tolerance [46]. Thus,
the B6.Sle1 mouse is a particularly attractive model for
testing the ability of Btk inhibition to modulate the
Figure 5 Treatment of B6.Sle1.Sle3 mice with PCI-32765 results in reduction of splenomegaly. (A) PCI-32765 has no effect on mouse
weight. All mice were weighed before sacrifice. (B-C) PCI-32765 reduces splenomegaly, but not kidney size, as measured by weight or cell
number. Spleens and kidneys isolated from mice treated with PCI-32765 (n = 9) or vehicle (n = 8) were weighed prior to the creation of a single
cell suspension of each tissue. Cells were then counted on a Cellometer Auto M10 automated cell counter (Nexcelom Bioscience). Each data
point represents one mouse. Line represents mean ± standard error of the mean. *P < 0.05, **P < 0.005. Data were compared by two-tailed
Student’s t-test with Welch’s correction.
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humoral autoimmunity associated with lupus. Upon
treatment with PCI-32765, inhibition of Btk resulted in a
dampening of the Sle1-associated phenotype at both the
cellular and serological levels. It is clear from these stu-
dies in B6.Sle1 mice that Btk in B-cells is a critical B-cell
activation node in lupus development. While B6.Sle1
mice provide a model to investigate the role of humoral
immunity in SLE, single congenic Sle1 mice do not fully
develop lupus nephritis. Hence, the B6.Sle1.Sle3 bicon-
genic mouse model, which develops a more robust
lupus-like phenotype was next utilized. This model was
well suited to this study given the previously reported
roles of Btk in myeloid cell activation, and established
myeloid cell population defects attributed to the Sle3
locus. Importantly, PCI-32765 treatment markedly
reduces spleen size and renal infiltration of leukocytes as
well as renal damage in B6.Sle1.Sle3 mice. In these stu-
dies, we have observed a decrease in all peripheral B cell
populations in the PCI-32765 treated mice compared to
the vehicle, although B-cell development appears to be
relatively normal. Consistent with genetic data from
Btklow mice, these data suggest that a partial Btk signal is
enough to permit B-cell development while still mana-
ging to regulate the overall number of mature and acti-
vated B cells [15]. Btk inhibition led to significantly
reduced numbers of splenic plasmablasts (Table 1), con-
sistent with previous findings that Btk is necessary for
antibody production in a gene dosage-dependent manner
[13-15,32,47].
Contrary to a previous report, which suggested that Btk
repressed dendritic cell maturation and increased T helper
cell activation by dendritic cells [48], we found that PCI-
32765 treatment decreases splenic myeloid dendritic cells
as well as T cell activation (Table 1); these data may sug-
gest a dose-sensitive context for Btk in dendritic cells,
similar to previous experiments with Btklow mice in B cells
[12,15,44]. We have also demonstrated that treatment
with PCI-32765 significantly decreases the number of sple-
nic mast cells, corresponding with previous data that
demonstrate a role for Btk in mast cell activation [49].




SEM Vehicle Average PCI-32765 SEM PCI-32765 P-value
B220+ 3.97E+07 1.13E+07 9.06E+06 2.76E+06 *
Activated, B220+CD69+ 3.71E+06 9.33E+05 5.29E+05 9.19E+04 **
T1, B220+AA4.1+CD23- 1.64E+07 5.90E+06 2.95E+06 8.72E+05 *
T2, B220+AA4.1+CD23+ 1.60E+07 3.42E+06 4.02E+06 1.79E+06 **
Marginal zone, B220+AA4.1-CD23- 1.99E+06 5.05E+05 5.25E+05 1.92E+05 *
Follicular, B220+AA4.1-CD23+ 5.13E+06 1.89E+06 8.82E+05 2.18E+05 *
Plasmablast, B220+AA4.1-CD138+ 3.62E+06 9.24E+05 4.36E+05 7.13E+04 **
Germinal center, B220+GL7+ 8.61E+06 4.52E+06 8.72E+05 3.38E+05 NS
B1-like, B220+CD5+ 1.01E+06 2.62E+05 2.60E+05 3.93E+04 *
Myeloid
Myeloid DC, CD11b+CD11c+ 1.33E+07 2.76E+06 2.19E+06 4.28E+05 ***
Macrophage, CD11b+F4/80+ 1.32E+07 3.11E+06 2.15E+06 3.88E+05 **
CD11b+Ly6C+ 1.74E+06 5.54E+05 3.40E+05 6.72E+04 *
Neutrophils, CD11b+Ly6G+ 1.50E+07 3.51E+06 2.41E+06 4.16E+05 **
Mast cell, CD34+c-Kit+ 3.74E+06 9.87E+05 7.36E+05 2.54E+05 *
T cells
CD4+ 2.31E+07 4.00E+06 9.83E+06 9.76E+05 **
Activated, CD4+CD69+ 8.29E+06 1.36E+06 2.64E+06 1.01E+06 ***
Naïve, CD4+CD44-CD62L+ 9.73E+05 2.34E+05 5.68E+05 9.45E+04 NS
Central memory, CD4+CD44+CD62L+ 5.11E+06 7.89E+05 2.84E+06 3.49E+05 *
Effector memory, CD4+CD44+CD62L- 1.56E+07 3.04E+06 6.00E+06 7.58E+05 **
CD8+ 2.01E+07 3.86E+06 5.29E+06 8.23E+05 **
Activated, CD8+CD69+ 8.57E+06 1.60E+06 2.54E+06 1.17E+06 **
Naïve, CD8+CD44-CD62L+ 6.18E+03 3.33E+03 3.34E+03 2.65E+03 NS
Central memory, CD8+CD44+CD62L+ 5.64E+06 1.38E+06 9.08E+05 1.65E+05 **
Effector memory, CD8+CD44+CD62L- 1.45E+07 2.87E+06 4.38E+06 8.23E+05 **
Quantitative analysis of B6.Sle1.Sle3 splenic cell populations as determined by flow cytometry. All data are expressed as the mean (Average) and standard error
of the mean (SEM) of the data for the PCI-32765-treated (n = 9) or vehicle-treated (n = 8) splenocytes, which were compared by two-tailed Student’s t-test. *P ≤
0.05, **P ≤ 0.01, ***P ≤ 0.005, compared to vehicle; NS, not significant.
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Taken together, these decreases in multiple immuno-
competent cell populations, as well as the dampening of
lymphocyte activation, underscore the ability of PCI-32765
to curtail the aberrant cellular activation that drives lupus
pathogenesis.
Of note, inhibition of Btk also results in a decrease in B-
cell infiltration into the kidney. It has previously been
reported that intra-renal B-cells contribute to kidney
damage and interstitial inflammation [50-52]. Likewise,
renal damage was reduced in B6.Sle1.Sle3 mice that
received PCI-32765 compared to the vehicle, as evidenced
by decreased GN score and decreased glomerular size
(Figure 6A, C). However, given that splenic myeloid cell
populations are also decreased (Table 1) it is possible that
some of the beneficial effects of Btk inhibition may arise
from its impact on the myeloid cell compartment, which
also entails Btk signaling for optimal functioning. It has
previously been shown that Btk is involved in various mye-
loid cell-mediated processes in mast cells [1], neutrophils
[2,3], and macrophages [4,5], including bacterial clearance,
production of reactive oxygen species (ROS), and TLR sig-
naling. Moreover, PCI-32765 has previously been shown
to exert effects on myeloid cells in the prevention of
experimental arthritis [20].
In summary, we have shown that treatment of lupus-
prone mice with PCI-32765 results in greater than 75%
inhibition of Btk, which is sufficient to reduce autoanti-
body titers, similar to Btklow mice, which express 25% of
Figure 6 Decreased renal destruction and lymphocyte infiltration in B6.Sle1.Sle3 mice after inhibition of Btk signaling. (A) Inhibition of
Btk by PCI-32765 reduced renal damage. Paraffin-embedded kidneys were sectioned and stained with H&E before being scored by a pathologist
blinded to the sample identity. (B) Decreased number of renal lymphocytes in mice that received PCI-32765. Single cell suspensions were
prepared from kidneys isolated from mice treated with PCI-32765 or vehicle. After staining with antibodies specific for the indicated cell
populations, percentage cell numbers were multiplied by the total intra-renal cell number as determined by a Cellometer Auto M10 automated
cell counter (Nexcelom Bioscience). Each data point represents one mouse. Line represents mean ± standard error of the mean. *P < 0.05, **P <
0.005. Data were compared by two-tailed Student’s t-test with Welch’s correction. (C) Histopathological signs of renal damage. Shown are
representative photomicrographs of period acid Schiff (PAS)-stained kidney sections isolated from PCI-32765-treated (n = 9) or vehicle-treated
(n = 6) mice. All images were taken at 200 × total magnification. GN, glomerular nephritis.
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endogenous Btk levels [12,53]. This is accompanied by
marked reduction in both the number and the activation
status of T and B cells as well as the number of myeloid
cells. Since T cells lack Btk expression, it seems likely that
the decreased number and activation status of T cells is a
result of decreased activation cues from B cells and APCs.
Meanwhile, it seems plausible that the decrease in B cell
and APC numbers may be caused by either decreased
expansion resulting from suboptimal activation, increased
apoptosis, or both. Previous reports lend support to both
mechanisms as Btk has been shown to be critically impor-
tant in both myeloid [1-5] and B cell activation [13,14,50]
as well as in the negative regulation of apoptotic processes.
Relevant to our data, Btk is required for BCR-mediated
NF-B pro-survival signaling [7,8,54], and is an upstream
regulator of the anti-apoptotic protein bcl-xL in B cells fol-
lowing IgM stimulation [55]. Btk is also necessary for the
survival of macrophages following inflammatory stimula-
tion [56], and is a regulator of the ROS response in both B
cells [57] and neutrophils [58]. Furthermore, in vitro PCI-
32765 treatment of CD19+ cells isolated from patients
with CLL resulted in increased apoptosis in a dose-depen-
dent manner [19]. Thus, subdued proliferative expansion
as well as enhanced apoptosis could both have contributed
to the cellular changes observed following Btk inhibition
in lupus, and this warrants further systematic evaluation.
Taken together these data suggest that Btk signaling, as a
key mediator of B cell activation, antibody production, and
myeloid cell activation, is vital to the pathogenesis of SLE.
Modulating BCR-mediated and APC signaling and/or
survival by Btk inhibition results in decreased lymphoid
activation and expansion, without total depletion. Given
that total B cell depletion may not be optimal in SLE [6],
fine-tuning the responsiveness of these cells as opposed to
eliminating them completely may be a more viable thera-
peutic strategy in SLE. Therapeutically reducing the num-
ber of B cells to blunt autoimmunity comes with the
inherent risk of eliminating the natural ability to produce
antibodies against invading pathogens. Given that B cell
and plasmablast populations are decreased but not comple-
tely eliminated following PCI-32765 treatment, it is likely
that some degree of humoral immunity is preserved in
these animals; nevertheless, further investigation is neces-
sary to determine the full impact of PCI-32765 treatment
on both the primary and secondary immune responses.
Conclusions
PCI-32765 treatment significantly decreased the amount
of free Btk, and this dampened the development and acti-
vation of multiple peripheral cell types in the immune sys-
tem, and decreased lupus severity as indicated by reduced
autoantibody levels, splenomegaly, and renal disease.
Therefore, targeting Btk to decrease downstream signaling
in multiple cell types may be an effective therapeutic
approach in SLE.
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